Uscom

ASX MEDIA RELEASE

China 5 Year NMPA Certification for Uscom

SYDNEY, Australia, Monday 6th January 2020: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) today announced receipt of the China National Medical Products Administration (NMPA) extension regulatory certification for sale of the USCOM 1A device into China. The new NMPA extension certification for USCOM 1A was issued on the 23rd December 2019 and is valid for 5 years until 22nd December 2024. The certification is the third consecutive extension approval for the USCOM 1A.

This approval allows current distributors to resume USCOM 1A sales, while new distributors, with contracts conditional on receipt of the NMPA certification, are now free to begin selling USCOM 1A, and this new revenue is expected to begin immediately.

Uscom's China HQ, set up in Beijing in Nov 2018, will provide clinical and technical support for all Uscom devices approved in China. Under the leadership of Ms Teresa Guo, Uscom China has transformed the China distribution model to a new network which includes previous Uscom distributors plus an expanded network of new distributors, meaning Uscom now has more distributors penetrating into more territories. This expansion is planned to continue as Uscom China inducts additional distribution streams for uncovered territories over the coming year.

China, with an expected 2020 medical device market of $600 billion RMB (>$100B AUD), will replace Japan as the second-largest global medical device market after the United States. The BP+ and SpiroSonic product series, including the innovative SpiroSonic AIR, a revolutionary digital, induction charging, home care ultrasonic technology based on wireless telemetry coupled with the SpiroSonic AIR App, are currently in NMPA approval process. Uscom China's new distribution strategy provides an accessible sales network for these new Uscom products as the new NMPA approvals are received over the next 12 months.

Executive Chairman of Uscom, Professor Rob Phillips said *"This 5 year NMPA approval underwrites the expansion of our new Uscom China HQ, and feeds directly into our new revenue model. Our Director of China operations, Ms Teresa Guo, has established a new direct distribution network in China, based on growing our current long term partners while adding new partners. Over the coming 12 months we expect approvals for a number of new products in China, and these will be fed into our expanded direct distribution channels. China is one of the fastest growing medical device markets in the world, and Uscom is committed to this market with its rapidly expanding China team. The NMPA USCOM 1A extension approval and the new Uscom China operations is the beginning of new era for Uscom."*

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases. The USCOM 1A provides vital guidance for optimising management of sepsis and the administration of fluid, inotropes and vasoactive therapies in critical care monitoring. The BP+ SpiroSonic devices improve diagnosis and management of hypertension, heart failure, asthma, COPD and sleep disorders in the clinical and home care environments.

Uscom

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.
The USCOM 1A: A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.
The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary **SpiroReporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse spirometry outputs and generate summary reports.
For more information, please visit: **www.uscom.com.au**

Uscom Contacts

Rob Phillips
Executive Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary